BMY vs DCTH: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

BMY is the larger of the two ($121.58B market cap): the incumbent the market prices for continued execution (8.88x forward earnings, beta 0.19). DCTH is the smaller challenger ($655.23M), actually pricier on forward earnings (69.12x): more room to run, but more to prove. If you believe in growth, DCTH fits: analysts expect its revenue to rise 20% next year, against a 3% decline for BMY. If you believe in paying less for profit, BMY fits: it trades at 8.88x forward earnings, against 69.12x for DCTH.

BMY vs DCTH: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricBMYDCTHWhat it tells you
Market cap$121.58B$655.23MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E8.8869.12Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E13.19117.72Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.190.60Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range60% of range74% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book5.194.90How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: BMY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how BMY and DCTH affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and DCTH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and DCTH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Bristol Myers Squibb (BMY) do?

Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is working through a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.

Full BMY guide

What does Delcath Systems (DCTH) do?

Delcath Systems, based in New York, develops and sells percutaneous hepatic perfusion (PHP), a procedure that isolates the liver's blood supply, delivers a high dose of the chemotherapy drug melphalan directly to it, and runs the returning blood through filters before it re-enters the body. In the US the product is sold as HEPZATO KIT, approved by the FDA in August 2023 for adults with uveal melanoma (a rare eye cancer) that has spread to the liver and cannot be removed surgically. In Europe the same filtration device is sold as CHEMOSAT. Each HEPZATO treatment is a hospital procedure performed by an interventional radiology and surgical oncology team, so growth depends on how many cancer centers are trained and actively treating patients.

Full DCTH guide

BMY vs DCTH: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • BMY drivers: New product portfolio ramp; Oncology and immunology depth.
  • DCTH drivers: More treatment centers and more patients per center; Profitability and cash generation.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For DCTH, delcath sells essentially one product for one rare cancer.

BMY or DCTH: which should you pick?

If the story you believe is BMY's (New product portfolio ramp), BMY is the more direct way to own it; if it is DCTH's (More treatment centers and more patients per center), DCTH is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and DCTH guides.

BMY vs DCTH: the full fundamentals

BMY. At about $59.43 on November 20, 2026, Bristol Myers trades near 9 times forward earnings, still low relative to large-cap pharma peers, which reflects market skepticism about replacing patent-cliff revenue even after a fifth straight earnings beat in Q3. The 4.3% dividend yield and strong cash flow are the bull-case anchors, while consensus for only modest 2027 EPS growth (about $6.70 versus $6.45 for 2026) on lower revenue captures the bear case. The 24 analysts in Yahoo's consensus carry a mean target near $65.

DCTH. At about $18.78 a share (November 20, 2026) and roughly 36 million shares including pre-funded warrants, Delcath is valued near $650 million, or about 5.9 times trailing revenue and roughly 5.0 times after netting out cash. Trailing earnings are small, about $6.7 million once the fourth-quarter 2025 loss is included, so the price-to-earnings ratio is very high and swings with each quarter. Guidance of $115 million to $117 million for 2026 implies fourth-quarter revenue of roughly $26 million to $28 million, below the third quarter's $35.1 million, which suggests management is leaving room for uneven volume. Published analyst targets earlier in 2026 ranged from roughly $19 to $30, and the average of five targets tracked by Yahoo Finance is about $28.60.

Headline figures (approximate, November 2026): BMY shows revenue (ttm) ~$50.0 billion (Q3 2026 up ~6.9% YoY), q3 2026 adjusted eps $1.35 vs $1.17 consensus, operating margin ~32%, net income (ttm) ~$9.2 billion; DCTH shows revenue (ttm) ~$110 million, revenue growth (q3 2026, year over year) ~70%, net income (ttm) ~$6.7 million, gross margin (q3 2026) ~89%.

The bottom line: BMY vs DCTH

BMY and DCTH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BMY and DCTH exposure against your real portfolio. It is not an investment adviser.

Wondering how BMY or DCTH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Bristol Myers Squibb

Ask Walnut's AI anything about BMY and see how it fits what you own.

FAQ

What is the difference between BMY and DCTH?

+

Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. Delcath Systems, based in New York, develops and sells percutaneous hepatic perfusion (PHP), a procedure that isolates the liver's blood supply, delivers a high dose of the chemotherapy drug melphalan directly to it, and runs the returning blood through filters before it re-enters the body. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is BMY or DCTH the better stock?

+

Neither is universally better. BMY is the larger incumbent; DCTH is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, BMY or DCTH?

+

On forward P/E (as of November 2026), BMY trades at 8.88x and DCTH at 69.12x, so BMY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both BMY and DCTH?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of BMY vs DCTH?

+

BMY: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed, and consensus already pencils in lower revenue in 2027, with EPS up only about 4%. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook; the split admilparant readout in October 2026, which also came with protocol changes and a patient death the company said was likely unrelated, is a reminder of how quickly pipeline news can move the stock. Debt of about $45 billion against about $12.6 billion of cash, and litigation exposure, add further uncertainty. DCTH: Delcath sells essentially one product for one rare cancer. Uveal melanoma affects only a few thousand people a year in the US, and only a portion of them develop liver metastases that fit the HEPZATO label, so the current market has a ceiling. Sales are concentrated: two customers accounted for about 31% of revenue in the first nine months of 2026, and a third for about 6.5%, so a slowdown at one large hospital shows up quickly in the numbers. The fourth quarter of 2025 showed how lumpy volume can be, with a net loss of about $1.9 million after a guidance cut that sent the stock sharply lower. The procedure carries serious side effects, including blood count suppression, and the FDA label includes a boxed warning and a restricted distribution program, which limits how fast new sites can start. Competing systemic drugs, such as Immunocore's Kimmtrak and newer targeted agents in development, could change treatment sequencing. The colorectal and breast trials are randomized Phase 2 studies and may not succeed. Pricing and reimbursement, including 340B discounts and the Medicaid rebate agreement, can pressure realized prices. At about 5.9 times trailing sales and roughly 69 times forward earnings estimates, after a gain of about 89% in 2026, the valuation already assumes continued growth.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BMY or DCTH; figures are approximate and dated (as of November 2026). Verify current data before investing.